The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively evaluate the effectiveness of bedaquiline (and/or delamanid)- containing regimens in a large cohort of consecutive TB patients treated globally. This observational, prospective study is based on data collected and provided by Global Tuberculosis Network (GTN) centres and analysed twice a year. All consecutive patients (including children/adolescents) treated with bedaquiline and/or delamanid were enrolled, and managed according to WHO and national guidelines. Overall, 52 centres from 29 countries/regions in all continents reported 883 patients as of January 31st 2021, 24/29 countries/regions providing data on 100% of their consecutive patients (10-80% in the remaining 5 countries). The drug-resistance pattern of the patients was severe (>30% with extensively drug-resistant -TB; median number of resistant drugs 5 (3-7) in the overall cohort and 6 (4-8) among patients with a final outcome). For the patients with a final outcome (477/883, 54.0%) the median (IQR) number of months of anti-TB treatment was 18 (13-23) (in days 553 (385-678)). The proportion of patients achieving sputum smear and culture conversion ranged from 93.4% and 92.8% respectively (whole cohort) to 89.3% and 88.8% respectively (patients with a final outcome), a median (IQR) time to sputum smear and culture conversion of 58 (30-90) days for the whole cohort and 60 (30-100) for patients with a final outcome and, respectively, of 55 (30-90) and 60 (30-90) days for culture conversion. Of 383 patients treated with bedaquiline but not delamanid, 284 (74.2%) achieved treatment success, while 25 (6.5%) died, 11 (2.9%) failed and 63 (16.5%) were lost to follow-up.

Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort / Koirala, S; Borisov, S; Danila, E; Mariandyshev, A; Shrestha, B; Lukhele, N; Dalcolmo, M; Shakya, S R; Miliauskas, S; Kuksa, L; Manga, S; Aleksa, A; Denholm, J T; Khadka, H B; Skrahina, A; Diktanas, S; Ferrarese, M; Bruchfeld, J; Koleva, A; Piubello, A; Koirala, G S; Udwadia, Z F; Palmero, D J; Munoz-Torrico, M; Gc, R; Gualano, G; Grecu, V I; Motta, I; Papavasileiou, A; Li, Y; Hoefsloot, W; Kunst, H; Mazza-Stalder, J; Payen, M-C; Akkerman, O W; Bernal, E; Manfrin, V; Matteelli, A; Mustafa Hamdan, H; Nieto Marcos, M; Cadiñanos Loidi, J; Cebrian Gallardo, J J; Duarte, R; Escobar Salinas, N; Gomez Rosso, R; Laniado-Laborín, R; Martínez Robles, E; Quirós Fernandez, S; Rendon, A; Solovic, I; Tadolini, M; Viggiani, P; Belilovski, E; Boeree, M J; Cai, Q; Davidavičienė, E; Forsman, L D; De Los Rios, J; Drakšienė, J; Duga, A; Elamin, S E; Filippov, A; Garcia, A; Gaudiesiute, I; Gavazova, B; Gayoso, R; Gruslys, V; Jonsson, J; Khimova, E; Madonsela, G; Magis-Escurra, C; Marchese, V; Matei, M; Moschos, C; Nakčerienė, B; Nicod, L; Palmieri, F; Pontarelli, A; Šmite, A; Souleymane, M B; Vescovo, M; Zablockis, R; Zhurkin, D; Alffenaar, J-W; Caminero, J A; Codecasa, L R; García-García, J-M; Esposito, S; Saderi, L; Spanevello, A; Visca, D; Tiberi, S; Pontali, E; Centis, R; D'Ambrosio, L; van den Boom, M; Sotgiu, G; Migliori, G B. - In: REVISTA PORTUGUESA DE PNEUMOLOGIA. - ISSN 0873-2159. - (2021). [10.1016/j.pulmoe.2021.02.006]

Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

Saderi, L;Sotgiu, G;
2021-01-01

Abstract

The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively evaluate the effectiveness of bedaquiline (and/or delamanid)- containing regimens in a large cohort of consecutive TB patients treated globally. This observational, prospective study is based on data collected and provided by Global Tuberculosis Network (GTN) centres and analysed twice a year. All consecutive patients (including children/adolescents) treated with bedaquiline and/or delamanid were enrolled, and managed according to WHO and national guidelines. Overall, 52 centres from 29 countries/regions in all continents reported 883 patients as of January 31st 2021, 24/29 countries/regions providing data on 100% of their consecutive patients (10-80% in the remaining 5 countries). The drug-resistance pattern of the patients was severe (>30% with extensively drug-resistant -TB; median number of resistant drugs 5 (3-7) in the overall cohort and 6 (4-8) among patients with a final outcome). For the patients with a final outcome (477/883, 54.0%) the median (IQR) number of months of anti-TB treatment was 18 (13-23) (in days 553 (385-678)). The proportion of patients achieving sputum smear and culture conversion ranged from 93.4% and 92.8% respectively (whole cohort) to 89.3% and 88.8% respectively (patients with a final outcome), a median (IQR) time to sputum smear and culture conversion of 58 (30-90) days for the whole cohort and 60 (30-100) for patients with a final outcome and, respectively, of 55 (30-90) and 60 (30-90) days for culture conversion. Of 383 patients treated with bedaquiline but not delamanid, 284 (74.2%) achieved treatment success, while 25 (6.5%) died, 11 (2.9%) failed and 63 (16.5%) were lost to follow-up.
2021
Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort / Koirala, S; Borisov, S; Danila, E; Mariandyshev, A; Shrestha, B; Lukhele, N; Dalcolmo, M; Shakya, S R; Miliauskas, S; Kuksa, L; Manga, S; Aleksa, A; Denholm, J T; Khadka, H B; Skrahina, A; Diktanas, S; Ferrarese, M; Bruchfeld, J; Koleva, A; Piubello, A; Koirala, G S; Udwadia, Z F; Palmero, D J; Munoz-Torrico, M; Gc, R; Gualano, G; Grecu, V I; Motta, I; Papavasileiou, A; Li, Y; Hoefsloot, W; Kunst, H; Mazza-Stalder, J; Payen, M-C; Akkerman, O W; Bernal, E; Manfrin, V; Matteelli, A; Mustafa Hamdan, H; Nieto Marcos, M; Cadiñanos Loidi, J; Cebrian Gallardo, J J; Duarte, R; Escobar Salinas, N; Gomez Rosso, R; Laniado-Laborín, R; Martínez Robles, E; Quirós Fernandez, S; Rendon, A; Solovic, I; Tadolini, M; Viggiani, P; Belilovski, E; Boeree, M J; Cai, Q; Davidavičienė, E; Forsman, L D; De Los Rios, J; Drakšienė, J; Duga, A; Elamin, S E; Filippov, A; Garcia, A; Gaudiesiute, I; Gavazova, B; Gayoso, R; Gruslys, V; Jonsson, J; Khimova, E; Madonsela, G; Magis-Escurra, C; Marchese, V; Matei, M; Moschos, C; Nakčerienė, B; Nicod, L; Palmieri, F; Pontarelli, A; Šmite, A; Souleymane, M B; Vescovo, M; Zablockis, R; Zhurkin, D; Alffenaar, J-W; Caminero, J A; Codecasa, L R; García-García, J-M; Esposito, S; Saderi, L; Spanevello, A; Visca, D; Tiberi, S; Pontali, E; Centis, R; D'Ambrosio, L; van den Boom, M; Sotgiu, G; Migliori, G B. - In: REVISTA PORTUGUESA DE PNEUMOLOGIA. - ISSN 0873-2159. - (2021). [10.1016/j.pulmoe.2021.02.006]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/245654
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 27
social impact